With the aim of improving diabetes control and maintaining adequate glycemic levels, the companies Abbott and Novo Nordisk have integrated two technologies into a single digital support: a mobile app that allows blood glucose measurement and insulin dosing to be optimized.
In particular, it is related to the integration of Abbott Flash Glucose Monitoring System And this Smart insulin pens NovoPen 6 and NovoPen Eco Plus from Novo Nordisk, With this integration, people with insulin-dependent diabetes can access the information they need to control their glucose in the freestyle LibreLink app. The app, available for iOS and Android, allows access Reports detailing glucose levels and trends and insulin dosageAllows for shared decision making.
In addition to being a dose recording screen viewer, the pen can also have stored information Transfer to App via Scan, In this way, and taking a look at history, it is possible Check when and how much insulin the patient has taken Up to 800 injections total.
The system discriminates between an actual dose and a dose designed to check insulin flow, seeking to eliminate potential air bubbles prior to administration. This information can be accompanied by glucose levels. share with health professionals To help monitor and control diabetes.
The degree of glycemic control varies depending on the type of diabetes. In Spain, less than 30% of patients with type 1 diabetes have an HbA value1c Less than 7%, the standard range, should be defined clinically as good metabolic control. This percentage rises to 62.5% in the case of people with type 2 diabetes.
as he tells Dr Javier AmpudiaEndocrinology and Nutrition Specialist at the University Hospital of Valencia, “Las The reasons for poor glycemic control are many.Such as use of inappropriate treatment, lack of adjustment of insulin dosage, disparity in access to technologies applicable to diabetes, inadequate medical education in some cases, lack of insulin dosage, erratic behavior in insulin administration and/or lack of proper adherence -UP. Ultimately it can be said that Glycemic control of people with diabetes is clearly improveable and even more, if possible, in patients on insulin treatment”,
This expert warns that, , Adherence to treatment is important in diabetes, In recent years, the development of new insulins with a more physiological action profile that favors adherence has been unstoppable. However, many patients forget, with some frequency and consciously or not, to administer insulin or inject it after meals or incorrectly.,,
Like this, ,In recent years, devices such as smart pens or smart pens and smart caps have also been developed, which are designed to accurately know the dose administered and the timing of administration of insulin, which can help people with diabetes adhere to treatment. help to improve.says Dr Ampudia.
for his part, he Dr Jesus MorenoThe endocrinologist and head of the Diabetes Technology Consultancy at the General University Hospital of Ciudad Real warns that “Interpretation of glucose data is lame if it is not accompanied by dose of insulin administeredSince the latter has a clear influence on the former”,
for Juan Francisco Peran, President of the Spanish Diabetes Federation (FEDE), “These types of digital solutions are of great benefit to people with diabetes, because, by promoting greater knowledge about their health status, they also contribute improving your overall quality of life,,
However, in his opinion ,essential Promote more information and training Available on these technological options, so that patients are aware of them and can also discuss with their professional team all the benefits that this type of device can bring them in controlling their deformity. Similarly, with these new options, a more personalization of treatmentThis is something important to improve adherence and, at the same time, reduce complications arising from poor diabetes control.”,
In this regard, a mobile app that allows measurement of blood glucose and customization of insulin dosage, Jose Maria Barranco, Director of Market Access and Sales at Abbott in Spainemphasizes that “synergy and cooperation between different agents in the health sector is important. With this in mind, we continue to bet on research and cooperation with different agents for the benefit of people with diabetes ”
In this sense, Dr. A.S. francisco pazuelomedical director of novo nordiskconfirms “Great hope lies in the management and control of this pathology use of new technologies, In this case, it has been possible to work continuously on our Smart Pen, which enables wireless connectivity and the storage and transfer of data from the last 800 injections.,
